Keros Therapeutics develops protein therapeutics that modulate TGF-β family signaling for the treatment of hematologic, pulmonary and neuromuscular disorders. Its pipeline includes candidates for cytopenias in myelodysplastic syndromes and myelofibrosis, pulmonary arterial hypertension and diseases such as Duchenne muscular dystrophy. The company targets high unmet needs in blood cell production and tissue repair through precise pathway modulation.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 211.3 | — | 148.4 | — |
| Q2 2025 | 18.2 | — | -30.7 | — |
| Q3 2025 | 14.3 | — | -7.3 | — |
| Q4 2025 | 0.4 | — | -23.5 | — |
| Q1 2026 | 0.4 | -99.8% | -23.7 | -116% |
| Q2 2026 | 0 | -100% | -28.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: American Battery Technology Company (ABAT), Whitehawk Therapeutics, Inc. (WHWK), Hudson Technologies, Inc. (HDSN), Paloma Acquisition Corp I (PALO), Kaltura, Inc. (KLTR), Silvaco Group, Inc. (SVCO)